Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04013334Phase 2Unknown

MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

Role: lead

NCT01931046Phase 1Completed

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer

Role: lead

NCT01197209Phase 1Withdrawn

Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer

Role: lead

All 3 trials loaded